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ABSTRACT 
 The central nervous system (CNS) includes the brain and spinal cord, where both 
possess a blood to brain and a blood to cerebrospinal fluid (CSF) barrier.  The blood-
brain barrier (BBB) and blood-CSF barrier (BCSFB) regulate the passage of many 
molecules to maintain and protect these sensitive organs from harmful xenobiotics (i.e. 
drugs, pollutants, etc.) or physiologic changes (i.e. glucose, ion, or water composition).  
These barriers also express ABC transporters, including P-glycoprotein (Pgp) and breast 
cancer resistance protein (BCRP), which are known to contribute to efflux of endogenous 
toxins and therapeutics from the CNS.  Pgp and BCRP expression and activity are a 
crucial determinant of drug efficacy in the CNS and have been studied using global 
transporter knockout mouse models.  Since the CNS compartment and location of 
transporters is unique at each barrier site, a global knockout model does not address 
questions of how each barrier site contributes to ineffectiveness of drugs getting into the 
CNS.  This unique composition also makes developing therapeutic strategies more 
difficult.  In order to look at each barrier independently, we have attempted to generate 
conditional knockout mouse models of each transporter and in each barrier site.  Our 
BBB and BCSFB models will provide insight into the biology of drug movement within 
the CNS while considering each barrier site’s contribution. 
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CHAPTER 1.   INTRODUCTION 
The central nervous system (CNS) includes the brain and spinal cord, where both 
possess a blood to brain and a blood to cerebrospinal fluid (CSF) barrier.  The blood-
brain barrier (BBB) and blood-CSF barrier (BCSFB) regulate the passage of many 
molecules to maintain and protect these sensitive organs from harmful xenobiotics (i.e. 
drugs, pollutants, etc.) or physiologic changes (i.e. glucose, ion, or water composition). 
The Blood-CSF Barrier 
The blood-CSF barrier (BCSFB) contains two different types of barrier cells, 
choroid plexus (CP) epithelial cells present within the brain interior, and arachnoid 
barrier (AB) epithelial cells surrounding the cranial and spinal CSF that flows around the 
CNS. 
Arachnoid 
Among the brain barriers, the AB has been the least characterized.  Meningeal 
tissue, consisting of three layers, covers the brain surface.  The most exterior layer is the 
dura mater, followed by an inner layer of arachnoid mater, and then finally the pia mater 
that physically covers the brain.  The sub-arachnoid space (SAS), where CSF flows 
around the brain and spinal cord, lies between the AB and pia layers.  Another type of 
arachnoid cell extends from the AB layer into and through the SAS creating a web-like 
connection between the AB and pia.  These web-like cells are called the arachnoid 
trabeculae [1].  It should be made clear that arachnoid trabeculae cells do not have barrier 
functions and only the single layer of AB cells create a physical barrier between blood 
and CSF fluids.  Literature often uses the term “leptomeninges”, which includes the AB 
and pial layers of the meningeal tissue, but again only the AB has barrier properties.  The 
AB functions as a physical barrier as evidenced by the exclusion of an intravascular dye 
from the CSF, pia, and brain parenchyma by the AB [1, 2].  Similar to the CP and BBB, 
AB cells express tight junction proteins, such as claudin-1, zona occludin-1 (ZO-1), and 
junction adhesion molecules (JAMs), to create a physical barrier.  In addition, the AB 
expresses the epithelial markers desmoplakin, vimentin, and cytokeratin which most 
likely play a role in stabilization of tight junction formation by acting as intracellular 
links between junctions and the cell cytoskeleton [3, 4].  The AB also possesses a 
chemical barrier via expression of major ATP-binding cassette (ABC) transporters on the 
cell membrane surface (Figure 1-1A).  Within the family of ABC transporters, Pgp and 
BCRP expression have only been recently elucidated at the AB [5], therefore there is 
much more to be discovered about this barrier. 
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Choroid plexus 
The CP is located inside each of the four brain ventricles, functioning to produce 
CSF for the CNS.  CSF is a crucial for preventing brain injury, sustaining the buoyancy 
of the brain, and maintaining chemical homeostasis of factors circulating within the CSF 
[6].  Unlike the BBB, the CP has fenestrated capillaries without any barrier properties, 
meaning these capillaries do not exclude any substances from reaching the CP epithelial 
cells.  A single layer of epithelial cells forms the barrier layer of the CP. These CP cells 
express tight junction (TJ) proteins providing a physical barrier between the blood and 
CSF.  Claudin-3 is the most abundant, but CP cells also express claudin-1, claudin-2, 
claudin-11, JAMs and supporting proteins ZO-1, ZO-2, ZO-3 and cingulin [7].  In 
addition to these tight junctions, CP epithelium expresses cadherin-10, an adherens 
junction protein, and ?, ?-catenin scaffolding proteins to support and maintain the 
boundary between blood and CSF fluids [7]. 
Like the BBB, the CP also expresses drug transporters and drug-metabolizing 
enzymes creating a transport and enzymatic barrier.  Pgp, BCRP, multidrug resistance 
protein (MRP) 1, and MRP4 are members of the ABC transporter family and are the most 
highly expressed within the CP epithelium [6, 7].  Pgp has been reported to be expressed 
on the apical (CSF-facing) surface or sub-apically within the CP epithelium; however, the 
exact membrane localization and/or presence of Pgp at the CP have been controversial in 
the literature [7-10].  BCRP is present on the apical surface of CP cells (Figure 1-1C), 
while MRP1/4 are localized to the basolateral surface of the CP epithelium [8].  
Localization of BCRP at the CP suggests it is involved in facilitating substances into the 
CSF contrary to its function at the BBB where BCRP prevents substances getting into the 
brain from the blood.  Since BCRP is known to transport other endogenous compounds, it 
is possible that BCRP transports an endogenous substance required into the CSF, or that 
this is a mechanism for removing cellular waste products due to the lack of a blood 
barrier.  For those data that support Pgp expression on the apical CP surface, these 
explanations for why BCRP is located there may also apply. 
The Blood-Brain Barrier 
The blood-brain barrier (BBB), also called the neurovascular unit (NVU), is 
composed of brain endothelial cells, pericytes, neurons, astrocytes, and microglia [11].  
Within the NVU, each cell type plays a specific role to support and form the BBB.  Brain 
endothelial cells express several tight junction and adherens junction proteins to create a 
physical barrier between the blood compartment and the brain parenchyma [7]. Tight 
junctions, such as claudin-3, claudin-5, occludin, and JAMs are key proteins that 
eliminate the paracellular passage of substances.  Many of these tight junction proteins 
are linked to cytoplasmic scaffolding and regulatory proteins such as ZO-1, ZO-2, ZO-3, 
and cingulin to ensure maintenance of the BBB [12].  Disruption of claudin-3 or claudin-
5 has been shown to cause a severely compromised BBB, even causing death in mice that 
lack claudin-5 [12, 13].  Adherens junctions are also very important in maintaining an 
intact BBB, specifically vascular E-cadherin (VEC or Cdh5), ?, ?, and ?-catenin 
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scaffolding proteins.  These proteins work to hold endothelial cells together, giving the 
BBB structure and support as well as making it possible to form the essential tight 
junctions for barrier function [12].  Therefore, disruption of adherens junctions can also 
result in a compromised or leaky barrier. 
In addition to a physical barrier, brain endothelial cells possess a chemical barrier 
between the brain and the blood.  This chemical barrier is established by the expression 
of many transport proteins and enzymes on the BEC membrane surface.  These proteins 
maintain brain homeostasis by restricting access of xenobiotics, while simultaneously 
facilitating transport of compounds required for brain cell nutrition and survival (i.e. 
glucose, amino acids, lipids).  ABC transporters such as Pgp, BCRP, and various MRPs 
are expressed on the apical or blood-side of endothelial cell membranes of the BBB and 
are major contributors in efflux of substances back into the blood (Figure 1-1B) [6-8, 14-
18].  These neuro-protective proteins are efflux pumps and remove endogenously 
generated neurotoxic compounds back into the blood.  Brain endothelial cells are 
considered to be the primary barrier between the brain and the blood and if this is 
dysfunctional or leaky, transporters present on other cell types of the BBB (pericytes and 
astrocytic end feet) can act as a second line of defense [12]. 
Pgp and BCRP: Background and Clinical Relevance in the Brain 
Pgp and BCRP are two of the most studied efflux transporters in brain barriers.  
Pgp was the first ABC transporter to be discovered and BCRP followed over 20 years 
later [19-22]. 
P-glycoprotein (Pgp) 
The multidrug resistance (MDR) transporter, also known as Pgp, MDR1, or 
ABCB1, is encoded by the ABCB1 gene.  Humans have one isoform, ABCB1/MDR1, 
while rodents have two isoforms, Mdr1a and Mdr1b [22, 23].  Expression levels of 
Mdr1a and Mdr1b have been characterized to be tissue and age dependent, where Mdr1a 
is highly expressed in brain endothelial cells while Mdr1b is not [24, 25].  Mdr1a is 
expressed at the brain endothelial cell membrane as early as embryonic day 18 (E18) in 
mice and continues to increase in its expression until plateauing at post-natal day 28 
(P28) [12].  While Pgp is located and functions in the brain barriers, this protein is not 
expressed exclusively in the brain.  Pgp is highly expressed on the bile canalicular 
membrane in the liver, proximal tubules of the kidney, and apical surface of the intestinal 
epithelium [26, 27].  Substrates for Pgp are amphipathic and lipid-soluble, ranging in 
molecular weight between 300 and 1000 Daltons [22, 23].  Pgp is considered a 
promiscuous transporter because it transports a large variety of substrates that can include 
anticancer drugs, steroids, fluorescent dyes, and peptides [22].  Some of these compounds 
are also substrates for other ABC transporters such as BCRP.  For example, topotecan 
(topoisomerase I inhibitor) can be a substrate for three ABC transporters, Pgp, BCRP, 
and MRP4 [10]. 
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Breast cancer resistance protein (BCRP) 
Unlike Pgp, BCRP is a half transporter encoded by the ABCG2 gene, where each 
half produced must homodimerize with another to create a functional protein to transport 
its large range of substrates. These compounds are predominantly, but not limited to, 
chemotherapeutic agents. BCRP is most well known for transporting the 
chemotherapeutic drug mitoxantrone [21, 28] as well as some endogenous physiological 
molecules like protoporphrin IX and pheophorbide a, a chlorophyll breakdown product 
[29].  Similar to Pgp, BCRP is also expressed in multiple organs, including the bile 
canalicular membrane in liver, proximal tubule in kidney, and apical surface of the 
intestinal epithelium. 
Drug administration into the CNS and transporter protein effects on disease 
Both Pgp and BCRP block drug penetration into the CNS, decreasing the efficacy 
of drug treatments developed to target the CNS.  Therefore, drug treatment of diseases 
such as brain cancer, Parkinson’s disease, Alzheimer’s disease, and even fatal brain 
metastasis from other cancers (i.e. breast cancer) extremely difficult [30, 31].  Most 
chemotherapeutics or drug treatments are given through intravenous (IV) infusion while 
other treatment regimens require treatment to be given intrathecally (IT) by intralumbar 
injection in the lower spine.  While IV injections are the primary means for drug delivery 
into the CNS, the BBB and BCSFB hinder the distribution of therapeutics to the intended 
target.  A growing number of drugs are being given IT to better treat CSF disease [32], 
however, the contribution of AB drug transporters to CSF drug distribution has not been 
studied. 
Instead of directly affecting drug penetration, Pgp and BCRP have been 
implicated in modulating aspects of Alzheimer’s and Parkinson’s disease.  Alzheimer’s 
patients suffer from accumulation of ?-amyloid proteins in the brain, but it has been 
reported that Pgp and BCRP may efflux these proteins to protect the brain from its toxic 
accumulation [7].  Other literature has also shown that brain capillaries from Alzheimer’s 
patients have lower expression of Pgp resulting in decreased ?-amyloid clearance [33-
35].  Parkinson’s disease has also been linked to a reduction of Pgp in brain endothelial 
cells [36-38]. 
Animal models used to study drug concentrations in the CNS 
Many studies have utilized global transporter knockout (KO) animal models and 
analyzed the CSF as a surrogate for the amount of unbound drug available to the brain 
[39-42].  However, this approach does not address the question of how much each barrier 
contributes to the distribution of a drug within the CNS.  The location of each transporter 
within the AB, BBB, and CP barriers must be considered as they may have different 
efflux directions and in some cases functionally opposing one another.  For example, 
BCRP at the CP faces the CSF, facilitating drug entry into the CSF, while BCRP at the 
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BBB faces the blood, preventing drug penetration into the brain.  An alternative method 
would be to use mice with conditional KO (cKO) of transporter proteins at each barrier to 
estimate the functional contribution of that drug transporter at the AB, BBB, and CP. 
This experimental design is especially relevant for drugs given IT, since they do not 
come into contact with the BBB until exported into the blood by transporters in the 
BCSFB.  Understanding the independent roles each barrier has in protecting the brain 
from toxicities may give insight towards the more efficient treatment of CNS illness.  
New evidence using fluorescent tracer injections into the CSF suggests administration of 
compounds through the CSF can potentially expose the brain to a greater amount of 
compound (i.e. drugs).  This fluorescent tracer was shown to actually bathe or “wash out” 
the brain parenchyma and has been implicated as a main route for waste disposal for the 
CNS, including possible ?-amyloid clearance [43, 44].  Maybe this same principle applies 
to drugs injected into the CSF. 
Experimental Approach: Generating Transgenic Animals 
The goal of this study was to generate mice with conditional deletion of Pgp or 
BCRP in each of the barrier cell types; AB, BBB, and CP. Using the Cre-loxP system, we 
used tissue specific promoters to drive Cre expression within the AB [45], BBB [46], or 
CP [47].  Each model’s Cre expression was then characterized by mating the Cre mouse 
to a tdTomato fluorescent reporter mouse [48]. After characterization, each of the three 
Cre models were crossed with Pgp and BCRP-floxed mice to generate a cKO where only 
cells expressing the Cre enzyme (AB, BBB, or CP) would lose expression of Pgp or 
BCRP protein in that cell. 
Cre-loxP System 
Cre recombinase (Cre) is a 38kDa enzyme that recognizes loxP sites to mediate 
site-specific recombination between two loxP markers.  Each loxP site is 34 base pairs 
(bp) in length and consists of two 13 bp inverted repeats with an 8 bp spacer that provides 
orientation for the overall sequence.  If two loxP sites are in the same orientation within a 
linear DNA sequence, recombination initiated by Cre results in excision of the loxP-
flanked DNA sequence [49].  Using the Cre-loxP system allows for flexibility in that a 
floxed target mouse line can be bred with any type of Cre expressing mouse line.  As an 
example, breeding a Cre line that expresses the enzyme ubiquitously with a target floxed 
mouse can generate a global knockout mouse model.  It is also possible to use an 
inducible Cre line to study deletion of a target gene at different time points in 
development.  Using the Cre-loxP approach to generate global knockouts addresses issues 
traditional knockouts may have with lethality or infertility when the gene is deleted in the 
whole animal.  In spite of all its advantages, the Cre-loxP system has some disadvantages 
such as the difficulty in finding a promoter to drive Cre expression in a specific tissue or 
cell and as with all transgenic models, expression level and site of integration of the Cre 
transgene can affect its success [50]. 
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CHAPTER 2.   MATERIALS AND METHODS 
Animals 
Mice were used according to protocols approved by the St. Jude Children’s 
Research Hospital Committee on the Use and Care of Animals.  Cdh5-Cre [46, 51] (JAX 
stock #006137), vWF-Cre [47], LPV-Cre [47], and Ptgds-Cre mice were crossed to 
ROSA-tdTomato reporter (referred to as tdTomato) (JAX stock #007914) mice to 
validate the targeting of Cre expression in specific cell types such as endothelial cells, 
choroid plexus epithelial cells, and arachnoid barrier cells.  These three cell types 
represent all the brain barriers in the central nervous system, and eventually Cre mice will 
be crossed to mice carrying a specific floxed gene of interest.  
Generation of Ptgds-Cre Mice 
The mouse prostaglandin D2 synthase (mPtgds) promoter was PCR amplified 
from the BAC Clone RP23-389G18 (Gensat BX1999; purchased from Children’s 
Hospital Oakland Research Institute) with restriction sites MluI in the forward primer (5’-
gaCGCGTtggtccttccaagaggactg-3’) and EcoRI in the reverse primer (5’-
ccgGAATTCttgctcagagcagagcagg-3’). The 2018 bp amplified product was subsequently 
cloned into CL20MCremCherry vector (received from Dr. John Gray at St. Jude Vector 
Lab) at the MluI and EcoRI restriction sites. This CL20MCremCherrry (8971 bp) is a 
lentiviral vector that expresses Cre from a promoter that we replaced with the mPtgds
promoter.  The cloned mPtgds-CremCherry construct (9519 bp; to provide tissue specific 
expression of Cre and this construct also express mCherry so the tissue specificity could 
also be characterized in the pups) was then sequenced to validate its identity using the 
following sequencing primers (Forward 5’-aggcagggatattcaccatt-3’ and Reverse 5’-
gcaaacggacagaagcattt-3’). Further, this construct was linearized using MfeI and SfiI 
restriction enzymes to remove the bacterial sequences. Finally, this 5629 bp transgene 
was submitted to our transgenic core facility to microinject the transgene into FVB 
mouse oocytes to generate transgenic founders. The founder lines were bred until the 
mice were homozygous for the Cre transgene.  
Detection of the Zygosity of Ptgds-Cre Transgene Alleles by Multiplex Ligation-
Dependent Probe Assay 
Multiplex ligation-dependent probe assay (MLPA) was used for determination of 
the zygosity of transgene alleles.  During MLPA, an oligonucleotide ligation reaction was 
performed, followed by PCR using fluorescein-conjugated primer, such that the amount 
of PCR product generated for each genomic sequence is directly proportional to the 
number of input copies. For this assay, the genomic DNA samples were isolated from 
mouse tail using DNeasy Blood and Tissue Kit (QIAGEN #69506) and adjusted to 
approximately 10 ng/μL using DNA suspension buffer (TEKnova #T0221). The mice 
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bearing Cre transgene alleles were analyzed by using the MLPA Cre probe set to generate 
an amplification product of 117 bp. Three control probes were used to amplify control 
sequences elsewhere in the mouse genome were used with amplification products ranging 
in size from 108 bp, 114 bp and 136 bp [52]. Each probe set was composed of a 5’ and a 
3’ half-probe, each containing unique target specific sequence, stuffer sequence, and 
universal primer sequences on their 5’ and 3’ ends, respectively (Table 2-1) [52]. All 
probes were synthesized at the standard 25nmol (25N) scale of synthesis and purified by 
polyacrylamide gel electrophoresis (Invitrogen Life Technologies).  Synthesis scales refer 
to the amount of starting material present, not the amount of product produced.  3’ half-
probes were synthesized with a 5’ phosphate to facilitate ligation. 
MLPA was performed by incubating 50 ng DNA in 5 μL at 98°C for 5 min; after 
cooling to room temperature, it was mixed with 1.5 μL of Cre transgene specific probe 
mixture (containing 1.5 fmol each probe) and 1.5 μL SALSA hybridization buffer, then 
denatured at 95°C for 2 min and hybridized at 60°C for 16 hours. Hybridized probes were 
then ligated at 54°C for 15 min by addition of 32 μL ligation mixture. Following heat 
inactivation, 40 μL ligation reaction was mixed with 10 μL PCR mixture (SALSA 
polymerase, dNTPs, and universal primers, one of which was labeled with fluorescein 
(FITC)), and subjected to PCR amplification for 35 cycles. Primer sequences used for 
SALSA PCR were 5’-*GGGTTCCCTAAGGGTTGGA-3’ for the forward primer 
(*FITC labeled) and 3’-GTGCCAGCAAGATCCAATCTAGA-5’ (unlabeled) for the 
reverse primer. 
All reagents except probe mixes were from MRC-Holland (Amsterdam, The 
Netherlands). Amplification products were diluted in water (1:10) and then 1:9 in Hi-
Di™ formamide (Applied Biosystems, USA) containing 1/36 volume of GeneScan 500 
LIZ size standard (Applied Biosystems), to a final dilution of 20 to 200 fold, and then 
were separated by size on an 3730XL DNA Analyzer (Applied Biosystems / Life 
Technologies). Electropherograms were analyzed by GeneMapper® v5 (Applied 
Biosystems), and peak height data were exported to an Excel table. Normalization of 
peak height data was done by dividing each Cre transgene peak height by the average 
signal from three control probes, followed by division by a similar value calculated from 
a set of reference samples known to be heterozygotes for the transgene allele. This ratio 
reflects the copy number of the Cre transgene.  Control probe sets were used exactly as 
previously described [52]. The probe set consists of a 5’ half-probe and a 3’ half-probe. 
Each probe contains universal primer sequence, stuffer sequence, and target sequence, the 
latter of which is specific for the transgene being assessed. Total length of PCR product 
assessed by capillary electrophoresis is shown by the total product length.
Table 2-1. MLPA Cre 5’ and 3’ probe set sequences based on the mouse 
transgene. 
Probe Sequence 5’ Half Probe 3’ Half Probe
Universal GGGTTCCCTAAGGGTTGGA TCTAGATTGGATCTTGCTGGCGC 
Stuffer CGCTACTACTATTAGT AAACTAAATCTAC 
Target ATGGACATGTTCAGGGATCGCCA GGCGTTTTCTGAGCATACCTGGA 
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Transgene Localization in Ptgds-Cre Mice Using Fluorescence In Situ Hybridization 
(FISH) 
The St. Jude Cytogenetic Shared Resource Laboratory isolated lungs from a 
Ptgds-Cre mouse carrying two copies of the Cre transgene (determined by MPLA).  
Purified Ptgds-Cre plasmid DNA was labeled with a green-dUTP (Alexa Fluor 488, 
Molecular Probes) by nick translation. The labeled transgene probe was combined with 
sheared mouse DNA and hybridized to metaphase and interphase nuclei derived from the 
transgenic mouse lung fibroblast culture in a solution containing 50% formamide, 10% 
dextran sulfate, and 2X SSC. The initial FISH assay indicated that the sample had a very 
weak homozygous insertion into a probable chromosome 1 location. For the confirmation 
assay, the previous process was repeated with the labeled transgene probe and a red-
dUTP (Alexa Fluor 594, Molecular Probes) labeled chromosome 1 control probe 
(Pax3/RP23-260F1/1C4).  Both probes were combined with sheared mouse DNA and 
hybridized to interphase nuclei and metaphase chromosomes derived from the transgenic 
mouse lung fibroblast culture in a solution containing 50% formamide, 10% dextran 
sulfate, and 2X SSC. The chromosomes were then stained with 4,6-diamidino-2-
phenylindole (DAPI) and analyzed. Results indicated that the Ptgds-Cre transgenic mice 
have the Ptgds-Cre transgene homozygously inserted into chromosome 1.  The transgene 
insertion site is at a position that is 47% of the distance from the heterochromatic-
euchromatic boundary to the telomere of chromosome 1, an area that corresponds to band 
1D-E. 
Generation of Pgp-Floxed Mice 
The University of Connecticut Health Center Gene Targeting and Transgenic 
Facility made the targeting construct and produced mice carrying one floxed allele.  The 
targeting construct contains loxP sites flanking exon 4 of the ABCB1a gene as well as a 
PGKNeo cassette for embryonic stem (ES) cell selection (Figure 2-1A).  ES cells were 
cultured in selective media containing G418 and gancyclovir to find targeted clones.  
Surviving clones were then confirmed by long range PCR to have the correct targeted 
allele.  These targeted clones were subsequently injected into mouse blastocysts and 
implanted into a surrogate mother to generate chimeric mice.  Chimeric males were bred 
with wild-type female mice to check for germ line transmission of the targeted construct 
representing the F2 generation (coat colors blended if transmission successful).  The F2 
generation of mice were interbred until offspring became homozygous for the Pgp-floxed 
alleles.  We received sperm of the homozygous Pgp-floxed offspring from transgenic 
facility in Connecticut, which was used for in-vitro fertilization in C57BL/6 wild-type 
female mouse by the St. Jude Animal Research Center staff.  Offspring from this cross 
were interbred until again producing homozygous Pgp-floxed mice assessed by PCR.  
Deletion of exon 4 of ABCB1a gene, upon introduction of Cre, results in the lack of Pgp 
protein due to disruption of its transmembrane domain. 
Figure 2-1. Genomic targ
floxed mice. 
A.  Pgp-floxed mice.  B.  BC
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eting scheme for generating Pgp-floxed and
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Generation BCRP-Floxed Mice 
ES cells containing a targeting construct for BCRP were obtained from Dr. Mike 
Dean from the National Cancer Institute (NCI).  The targeting construct has loxP sites 
flanking exon 2 of the ABCG2 gene as well as a Neo cassette for ES cell selection 
(Figure 2-1B).  Upon arrival, ES cells were cultured in selective media containing G418 
and surviving clones were analyzed by Southern hybridization to confirm a correctly 
targeted allele.  Four correctly targeted clones were sent to the St. Jude Transgenic Core 
Facility where these clones were injected into individual mouse blastocysts, then 
implanted into a surrogate mother to generate chimera mouse offspring. Chimeric males 
were bred with C57BL/6 wild-type female mice to check for germ line transmission of 
the targeted construct representing the F2 generation (coat colors blended if transmission 
successful).  The F2 generation of mice were interbred until offspring became 
homozygous for the BCRP-floxed alleles as accessed by PCR and MLPA.  Deletion of 
exon 2 of ABCG2, in cells expressing Cre, results in the lack of BCRP mRNA or protein 
being made. 
Whole Organ Fluorescence Analysis 
Offspring from all Cre-tomato crosses were collected at two different ages, early 
post-natal (P5-7) and adult (6-10wks).  Animals were subsequently anesthetized by 
isofluorane and perfused through the heart with cold 1x phosphate buffered saline (PBS) 
followed by cold 4% paraformaldehyde (PFA, Electron Microscopy Sciences #15710) 
diluted in 1xPBS, which was performed by St. Jude Veterinary Pathology Core staff.  
Following perfusion, brain, liver, kidneys, and small intestine were removed for whole 
tissue fluorescent analysis on a stereoscope (Nikon SMZ1500 stereoscope with Nikon 
Intensilight CGFI fluorescence source) where the TRITC filter was used to examine 
tdTomato expression.  Tissues from all Cre-tomato crosses were processed for frozen or 
paraffin slides and further examined by immunofluorescence (IF) or 
immunohistochemistry (IHC) respectively after whole organ images were captured. 
Immunofluorescence on Frozen Tissue and Image Analysis 
Mouse tissues were fixed in 4% PFA overnight at 4°C, then sucrose protected by 
incubating them in 15% sucrose in 1xPBS overnight at 4°C, then 30% sucrose in 1x PBS 
overnight at 4°C.  The next day, tissues were equilibrated in OCT compound (Tissue Tek 
#4583, Electron Microscopy Sciences) for 30 minutes, embedded in a mold with OCT, 
then frozen in an ethanol bath chilled on a metal block on dry ice.  Frozen blocks were 
then transferred to the -80°C freezer for storage until sectioning.  Blocks were removed 
from the freezer and allowed to equilibrate inside the cryostat (Leica) -20°C chamber for 
at least 1 hour before sectioning at 15?m thickness.  Slides were stored at -80°C until 
IHC could be performed.  Slides thawed on a slide warmer at 37°C for 15-30 minutes 
followed by two 10-minute washes with 0.3% Triton X-100 in 1xPBS (PBST).  Slides 
were blocked with 3% normal donkey serum diluted in PBST (PBST+) for 60 minutes 
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followed by an overnight incubation in desired primary antibody (diluted in PBST+) at 
4°C (Table 2-2).  After primary antibody incubation, slides were washed in PBST three 
times for 10 minutes each.  Slides were then incubated with appropriate secondary Alexa 
Fluor 488, 555 or 647 antibodies (Invitrogen), diluted 1:500 in PBST+, for 2-3 hours.  
After secondary incubation, slides were washed in PBST four times for 10 minutes each 
followed by mounting with Prolong Gold anti-fade with DAPI (Invitrogen #P36935) and 
#1 cover-slips (Thermo Scientific #102450). Images were captured on a Nikon E800 
using the 20x dry objective or Marianas confocal microscope using the 40x oil objective.  
After capture, images were processed by ImageJ software (64bit, version 1.46r) to 
remove non-specific background by adjusting the color range using color balance tools 
provided by the ImageJ software. 
Immunohistochemistry on Paraffin Embedded Tissue and Image Analysis 
Tissues from conditional knockout mouse models were perfused and left to fix in 
4% PFA overnight at 4°C, then processed for paraffin slides by the St. Jude Veterinary 
Pathology Core.  Tissues were sectioned at 4?m thickness and slides were stored at room 
temperature until IHC could be performed.  Slides were deparaffinized and hydrated 
through a series of xylene and alcohols according to typical histology practices.  Slide 
underwent antigen retrieval through incubation in Target Retrieval Buffer, pH 6.0 
(DAKO #S1699) for 15 minutes at high pressure within a pressure cooker system.  After 
retrieval, tissues on slides were peroxidase blocked with 0.3% peroxide and protein 
blocked with Sniper Block reagents (Biocare Medical #BS966L).  Slides were 
subsequently stained with Pgp or BXP-53 primary antibody overnight at 4°C.  After 
primary antibody incubation, slides were washed in PBST and then incubated with their 
respective secondary HRP-polymer (Rabbit on Rodent, Biocare Medical #RMR622H; 
Rat on Rodent, Biocare Medical #RT517H) for 30 minutes.  Slides were washed in PBST 
and incubated with 3,3’-diaminobenzidine chromagen (DAB; Thermo Scientific #TA-
125-HDX) for 3 minutes.  Slides were washed in PBST and then counterstained with 
Mayer’s hematoxylin (Thermo Scientific #TA-125-MH) that was diluted 1:5 in distilled 
water and filtered prior to applying to slides for 3 minutes.  Slides were washed in PBST 
and dehydrated through a series of alcohols and xylene.  Slides were then mounted with 
Permount (Fisher #SP15-500) and coverslipped.  Slides were left on a flat surface until 
dry, then examined on a Nikon Eclipse Ti microscope with a 10-20x dry objective. 
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Table 2-2. Primary antibody dilutions, host species, and manufacturer 
information for immunofluorescence and immunohistochemistry. 
Antibody IF Dilution IHC Dilution Host Species Manufacturer 
Pgp 1:50,000 1:400,000 Rabbit Dr. John Schuetz, SJCRH 
BXP-53 1:2,000 1:2,000 Rat Enzo #ALX-801-036 
CD31 1:300 n/a Goat R&D Systems #AF3628 
GFAP 1:500 n/a Rabbit DAKO #Z0334 
Desmin 1:200 n/a Mouse Novus Biologicals #NBP1-42133 
Notes:  BXP-53 (BCRP antibody), CD31 (endothelial surface marker), GFAP (glial 
filament associated protein), Desmin (pericyte marker).  The Pgp antibody was obtained 
from Dr. John Schuetz at St. Jude Children’s Research Hospital (SJCRH) in Memphis, 
TN.  A peptide (SALDTESEKVVQEALDKAREG) coupled to KLH was synthesized 
and sent to Rockland Immunochemicals for injection into rabbits to generate the IgG 
antibody.  The Pgp antibody in the rabbit serum was purified by Invitrogen (previously 
Research Genetics) in 2000.  The epitope of this antibody recognizes an internal and 
highly conserved amino acid sequence on the C-terminal region of Pgp.  The classical 
MDR1 antibody is the monoclonal C219, but this antibody detects a 200kDa protein 
migrating in the same position as myosin, cross-reacts with cerbB2 protein (p185cerbB2), 
and recognizes MDR1 and MDR3 isoforms of Pgp.
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CHAPTER 3.   RESULTS 
Characterization of Mice Expressing Cre/tdTomato in AB Epithelial Cells 
Since there is no Cre transgenic mouse model that targets AB cells, a new AB-Cre 
model was generated.  The aim was to find a promoter that would drive expression of Cre 
in arachnoid cells but not in endothelial cells, CP epithelial cells, or other organs.  After 
surveying published literature and expression analysis through databases such as the 
Allen Brain Institute (ABI) and Gensat, these sources indicated that since both AB and 
CP epithelial cells are from a common embryonic origin, it would be possible to generate 
AB/CP specific cKO mice representing the BCSFB.  The ABI uses in situ hybridization 
to look at mRNA expression of genes in the developing and adult mouse brain, while 
Gensat uses transgenic mice where promoters of various genes drive green fluorescent 
protein (GFP) expression to look at their localization in the mouse developing and adult 
brain.  L-prostaglandin D synthase (Ptgds) was one of the most highly expressed genes in 
AB cells and never indicated to be expressed in brain endothelial cells per evidence 
described in published literature and databases described above.  Ptgds was chosen to 
generate the new AB-Cre model.  Ptgds has a dual function in the CNS, one where it is 
secreted into the CSF, presumably from AB or CP cells, and another serving as a 
transporter protein that binds lipophilic ligands and retinoid molecules [53].  In regards to 
its localization, Ptgds has been reported in the leptomeninges (arachnoid and pia 
meninges), CP, and oligodendrocytes within the CNS as well as the pigment layer of the 
retina, and leydig cells of the testis using in-situ hybridization (ISH) and IHC techniques 
[45, 54-57].  An example of Ptgds mRNA expression in mouse brain from ABI can be 
seen in Figure 3-1B. 
After producing a founder that gave viable offspring and maintained Cre 
expression, Ptgds-Cre mice were bred to maintain homozygosity of the Cre transgene and 
subsequently crossed with the tdTomato reporter (Figure 3-1A).  Seven out of eight 
(88%) offspring were positive for tdTomato fluorescence and gender did not influence 
fluorescence expression.  However, increasing age seemed to correlate with increase in 
tdTomato signal meaning older mice had more tdTomato expression than young mice 
(Figure 3-1C).  Ptgds-Cre/tomato offspring expressed tdTomato in a variety of cell types 
including, AB cells, some cell in the NVU (possibly endothelial cells), CP epithelium, 
liver hepatocytes, kidney tubules, and intestinal epithelium (Figure 3-1D).   
IHC was used to elucidate which cells of the NVU were expressing tdTomato.  
The NVU is composed of endothelial cells, pericytes, and astrocytes.  Using the vascular 
marker CD31 we concluded that tdTomato, driven by the Ptgds promoter, was likely 
expressed in endothelial cells of the brain due to the overlapping pattern seen between 
CD31 (green) and tdTomato (red) in Figure 3-2A.  Co-localization of colors green and 
red result in orange color, but sometimes intensity of one color is greater than the other 
resulting in a more red or a more green overlap.  We ruled out Cre expression in other 
cell types that contribute to the NVU, such as pericytes and astrocytes, using their 
respective markers desmin and glial fibrillary acidic protein (GFAP).  These IHC studies  
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Figure 3-1. TdTomato reporter expression in Ptgds-Cre/tomato mice. 
A.  Activation of the tdTomato reporter when bred with Ptgds-Cre mice.  B.  ISH (left 
panel) and expression (right panel) analysis of endogenous Ptgds mRNA in adult mouse 
brain from the Allen Brain Atlas.  The colored scale bar represents level of expression; 
blue being the lowest expression and red being the highest expression.  Clearly, the 
leptomeninges and choroid plexi are highly expressing Ptgds.  C.  Representative images 
of tdTomato expression of whole brain, liver, kidney, and intestine from age matched 
Ptgds-Cre/tomato and control (Cre negative) tomato mice (pups n = 6, adults n = 10).  D.  
Representative images of frozen sections of Ptgds-Cre/tomato (n = 8) and control (Cre 
negative) tomato brain, liver, kidney, and intestine at 20X magnification.  Dashed lines 
indicate the edge of the arachnoid barrier tissue on the surface of the brain. 
Notes:  Cell nuclei (blue) are stained with DAPI.  Red color represents the tdTomato 
fluorescent reporter, which is an indicator of Cre expression. C, brain cortex.  CB, 
cerebellum.  AB, arachnoid barrier.  BBB, blood-brain barrier.  CP, choroid plexus. 
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Figure 3-1. Continued.
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Figure 3-2. Immunohistochemistry with NVU markers to validate tdTomato 
expression in the brain of Ptgds-Cre/tomato mice. 
A.  Frozen brain sections stained with CD31 (endothelial cells in green), while Cre is 
expressed by tdTomato in red.  B.  Frozen brain sections stained with pericyte marker 
Desmin (green), while Cre is expressed by tdTomato in red.  C. Frozen brain sections 
stained with antibodies to GFAP (astrocytes in grey) and CD31 (endothelial cells in 
green), while Cre is expressed by tdTomato in red. 
Notes:  Cell nuclei (blue) are stained with DAPI and all images were captured at 40X 
magnification.  AB, arachnoid barrier.  BBB, blood-brain barrier.  CP, choroid plexus. 
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showed little overlap between pericyte and astrocyte markers with tdTomato fluorescence 
(Figure 3-2B and C).  This result further supported tdTomato expression within brain 
endothelial cells of the Ptgds-Cre model.  TdTomato expression was seen in brain 
endothelial cells of seven out of eight animals characterized.  The remaining animal was 
the only one negative under stereoscope and tissue section analysis.  AB expression of 
tdTomato in the Ptgds-Cre/tomato mice was also varied yielding five positive animals out 
of eight.  The remaining three animals were either negative from stereoscope analysis or 
at a young postnatal age (P4) with tdTomato expression only in the brain endothelial 
cells.  According to the ABI, Ptgds expression begins at embryonic age 13.5 (E13.5) and 
should be fully expressed in mice at E18.5, so these young pups should be positive for 
tdTomato at P4.  Other published literature also supports expression of Ptgds in 8-13 
week old rats [55]. 
Another striking result was the inconsistency of CP expression in our Ptgds-Cre 
model.  CP expression of tdTomato was seen in only one out of eight (12.5%) animals, 
whereas the literature indicated the Ptgds gene would also be highly expressed in CP.  
Animals negative for CP expression of tdTomato were of varying ages P4 through 7 
weeks old, resulting no correlation with age.  The animal with positive tdTomato in CP 
was 6 weeks old.  This unexpected expression may be due to the Ptgds-Cre transgene 
insertion location within the mouse genome.  FISH analysis revealed insertion of the 
Ptgds-Cre transgene into chromosome 1 within band regions D-E, but this location is not 
specific enough to say whether or not the insertion is interfering with any essential genes.  
Specifically genes or genetic elements that cause reduced expression of tdTomato in the 
CP or cause tdTomato expression to be in the brain endothelial cells. 
The tdTomato expression in liver, kidney, and intestine was also analyzed by the 
same IHC method, where CD31 and transporter markers were used.  This was done to 
compare native tdTomato expression in respect to Pgp and BCRP localization in the 
brain, liver, kidney, and intestine as well as vasculature sites within these organs.  Slides 
with sequential frozen sections of brain, liver, kidney, and intestine tissue from Ptgds-
Cre/tomato mice were used.  Using sequential sections allows for comparison of similar 
areas when looking at expression of different proteins.  For example, brain sections 
stained for Pgp, CD31, and BCRP were only 15 ?m apart making it easier to correlate a 
location relationship between all three markers.  As stated previously, CD31 and 
tdTomato seem to co-localize in endothelial cells of the brain, but there seems to be a 
lack of co-localization in the vasculature of peripheral tissues, except for in the intestine 
and possibly the liver (Figure 3-3B).  The tdTomato expression in liver, kidney, and 
intestine also seemed to vary animal-to-animal.  We confirmed Pgp and BCRP 
expression in the AB and BBB, while Pgp and BCRP had differing expression patterns in 
the CP.  Pgp is not expressed in mouse CP, but BCRP was expressed on the apical (CSF-
facing) surface of CP epithelial cells (Figure 3-3A).  IHC analysis confirmed the 
presence of Pgp and BCRP within the bile canaliculi of liver, kidney tubules, and apical 
surface of intestinal epithelium seen in Figure 3-3B.  By comparing transporter 
localization at each tissue site with tdTomato expression, we concluded that Pgp and 
BCRP will be deleted in the AB and BBB of the brain, as well as kidney tubules of 
Ptgds-Cre mice when bred with transporter floxed mice.
 21
Figure 3-3. Immunohistochemistry with CD31, Pgp, and BCRP markers in 
comparison to native tdTomato expression in Ptgds-Cre/tomato mice. 
A.  Sequential frozen brain sections stained with CD31 (endothelial cell marker), Pgp, 
and, BXP-53 (BCRP) antibodies.  Images captured at 20X magnification.  B.  Sequential 
frozen liver, kidney, and intestine sections stained with CD31 (endothelial cell marker), 
Pgp, and, BXP-53 (BCRP) antibodies.  Images captured at 20X magnification. 
Notes:  Arrows indicate the edge of the AB layer.  Cell nuclei (blue) are stained with 
DAPI.  Red color represents the tdTomato fluorescent reporter, which is an indicator of 
Cre expression.  Green color indicates antibody staining for CD31, Pgp, or BCRP.  AB, 
arachnoid barrier.  BBB, blood-brain barrier.  CP, choroid plexus. 
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Figure 3-3. Continued. 
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Characterization of Mice Expressing Cre/tdTomato in Endothelial Cells 
 Two mouse models targeting endothelial cells were analyzed, one using the vWF 
promoter and another using the vascular E-cadherin (Cdh5 or VEC) promoter to drive 
Cre expression in mouse endothelial cells.  The vWF-Cre model was the first to be 
characterized, but due to heterogeneous results an alternative model was needed and 
Cdh5-Cre was chosen. 
vWF-Cre model targeting brain endothelial cells 
The previously characterized mouse model vWF-Cre, was generated by Dr. 
Rodney Ho and had shown positive Cre expression specifically in brain endothelial cells 
[47].  Von Willebrand factor (vWF) is large glycoprotein produced by endothelial cells 
that binds and stabilizes Factor VIII (clotting cascade component) in the circulation [58].  
After breeding vWF-Cre mice with the tdTomato reporter (Figure 3-4A), the resulting 
offspring showed that Cre, as expressed by tdTomato fluorescence, was not uniform in 
any tissues or cell types, varied among animals, and was not confined to the brain shown 
by whole organ stereoscope and frozen tissue sections (Figure 3-4B and C).  Some 
brains were completely negative for tdTomato while others expressed the fluorescent 
reporter in only one brain hemisphere (Figure 3-4B).  Tissue sections also revealed 
cellular heterogeneity of Cre expression in brain endothelial cells, choroid plexus 
epithelial cells, intestinal epithelium, and hepatocytes (Figure 3-4C). 
IHC with the vascular marker CD31 was the final test to see how well the vWF-
Cre model would work for us.  The conclusion was that CD31 hardly ever co-localizes 
with the tdTomato expression due to the lack of tdTomato expression in endothelial cells 
of the vWF-Cre/tomato model (Figure 3-5).  Co-localization of CD31 (green) and 
tdTomato (red) should result in an orange color, in which analysis of the vWF-Cre/tomato 
model showed little to none.  Arteries at the brain surface were also negative for 
tdTomato expression indicating this was not just a phenomenon of small vessels or 
capillaries.  No correlation could be concluded about any expression difference between 
genders due to its highly sporadic expression pattern.  Based on age, generally, adult 
mice (6-10wks) positive for tdTomato had a slightly higher expression level than pups 
(P5), but ultimately our findings indicate that this model is not be suitable for targeting 
endothelial cells in hopes of generating a conditional knockout mouse.  It has been 
reported that the portion of the promoter used to make the vWF-Cre mouse does not 
target all endothelial cells, which supports what we have seen in the brain vasculature 
[59, 60]. 
Cdh5-Cre model targeting endothelial cells 
Characterization began again with the Cdh5-Cre mouse model distributed by 
Jackson Laboratories. The Cdh5 gene encodes a transmembrane vascular E-cadherin 
protein also known as CD144, which has been shown to be required for the maintenance 
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Figure 3-4. TdTomato reporter expression in vWF-Cre/tomato mice. 
A.  Activation of the tdTomato reporter when bred with vWF-Cre mice.  B.  
Representative images of tdTomato expression of whole brain, liver, kidney, and intestine 
from age matched vWF-Cre/tomato and control (Cre negative) tomato mice (pups n = 8, 
adults n = 9).  Multiple animals are included to show the heterogeneity of tdTomato 
expression for this model.  C.  Representative images of frozen sections of vWF-
Cre/tomato (n = 7) and control (Cre negative) tomato brain, liver, kidney, and intestine at 
20X magnification. 
Notes:  Cell nuclei (blue) are stained with DAPI.  Red color represents the tdTomato 
fluorescent reporter, which is an indicator of Cre expression.  AB, arachnoid barrier.  
BBB, blood-brain barrier.  CP, choroid plexus.  
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Figure 3-4. Continued. 
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Figure 3-5. Immunohistochemistry with CD31 in comparison to native tdTomato 
expression in vWF-Cre/tomato mice. 
Frozen brain, liver, kidney, intestine sections stained with CD31 (endothelial cell marker) 
antibody.  Cell nuclei (blue) are stained with DAPI.  Red color represents the tdTomato 
fluorescent reporter, which is an indicator of Cre expression.  Green color indicates 
antibody staining for CD31 as indicated.  Images captured at 20X magnification. 
Notes: AB, arachnoid barrier.  BBB, blood-brain barrier.  CP, choroid plexus. 
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of selective properties of the endothelial cells of the BBB [46, 51].  Cdh5-Cre mice were 
crossed with tdTomato reporter mice (Figure 3-6A) and all resulting offspring were 
positive for tdTomato fluorescence, an output of Cre, in endothelial cells.  TdTomato 
fluorescence was not different between male and female mice, but did seem to increase 
(more intense tdTomato fluorescent signal) with increase in age from P7 to adult (6 
weeks) by whole organ stereoscope analysis (Figure 3-6B). 
Upon examining tissue sections for this difference, all ages seemed equal in 
intensity (Figure 3-6C), so the differential may be an artifact of looking at whole organs 
versus thin tissue slices.  Cdh5-Cre/tomato mice show fluorescent signal in the brain 
vasculature including choroid plexus fenestrated capillaries as well as endothelial cells in 
liver, kidneys, and intestine shown in Figure 3-6C.  Its important to note that this model 
does not express tdTomato in the other CNS barrier cells, such as AB or CP epithelium; 
as our goal is to target one barrier at a time.  IHC with endothelial cell marker CD31 was 
performed on frozen tissue sections to again look at the co-localization of CD31 (green) 
and tdTomato (red).  We expected to see co-localization (yellow/orange color) in 
endothelial cells from all organs examined and our results show this (Figure 3-7A and 
B). 
In addition to CD31 IHC, we also performed this experiment with antibodies to 
our ABC transporters of interest, Pgp and BCRP, to show their location in comparison to 
the tdTomato expression.  Pgp and BCRP are expressed at the luminal surface of brain 
endothelial cells and play a major role in drug efflux from the brain parenchyma into the 
blood. However, these ABC transports are not found in peripheral endothelial cells, for 
example in the vasculature of organs such as liver, kidneys, or intestine.  We found in our 
Cdh5-Cre/tomato mice that the brain endothelial cells, which make up a portion of the 
BBB, express tdTomato, Pgp, and BCRP as seen by the similar vascular staining pattern 
in Figure 3-7A. Using this model we can conditionally knockout Pgp or BCRP in the 
brain endothelial cells exclusively since Pgp or BCRP are not expressed in any 
endothelial cells outside the CNS. 
Characterization of Mice Expressing Cre/tdTomato in CP Epithelial Cells 
In addition to vWF-Cre, Dr. Rodney Ho generated a LPV-Cre mouse model to 
target the choroid plexus epithelial cells to express Cre [47].  This model differs from 
others in that it uses a viral control region, specifically a lymphotropic papova virus, to 
drive Cre expression in the transgenic animal.  It has been reported in the literature that 
by using this control region to drive SV40 expression, CP specific tumors arise in mice 
[61, 62].  In order to validate this finding and analyze other brain barriers, we crossed the 
LPV-Cre mice with the tdTomato reporter (Figure 3-8A).  Resulting offspring should 
express tdTomato in the CP epithelium only, indicating those cells express the Cre 
enzyme.  The tdTomato expression could not be visualized by whole organ stereoscope 
due the internal location of the CP in the brain, but stereoscope analysis did confirm all 
other organs to be negative for tdTomato (Figure 3-8B).  Tissue sections were examined 
to look for tdTomato expression in the CP, where we found the CP was positive but very 
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Figure 3-6. TdTomato reporter expression in Cdh5-Cre/tomato mice. 
A.  Activation of the tdTomato reporter when bred with Cdh5-Cre mice.  B. 
Representative images of tdTomato expression of whole brain, liver, kidney, and intestine 
from age matched Cdh5-Cre/tomato and control (Cre negative) tomato mice (pups n = 9, 
adults n = 9).  C.  Representative images of frozen sections of Cdh5-Cre/tomato (n = 7) 
and control (Cre negative) tomato brain, liver, kidney, and intestine at 20X magnification.  
Dashed lines in the AB column indicate the edge of the arachnoid barrier tissue on the 
surface of the brain.  Dashed lines in the CP column indicate to boundary of the brain 
ventricle that contains the CP. 
  
Notes:  Cell nuclei (blue) are stained with DAPI.  Red color represents the tdTomato 
fluorescent reporter, which is an indicator of Cre expression.  AB, arachnoid barrier.  
BBB, blood-brain barrier.  CP, choroid plexus.  
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Figure 3-6. Continued. 
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Figure 3-7. Immunohistochemistry with CD31, Pgp, and BCRP markers in 
comparison to native tdTomato expression in Cdh5-Cre/tomato mice. 
A.  Sequential frozen brain sections stained with CD31 (endothelial cell marker), Pgp, 
and, BXP-53 (BCRP) antibodies.  Images captured at 20X magnification.  B.  Sequential 
frozen liver, kidney, and intestine sections stained with CD31 (endothelial cell marker), 
Pgp, and, BXP-53 (BCRP) antibodies.  Images captured at 20X magnification. 
  
Notes:  Cell nuclei (blue) are stained with DAPI.  Red color represents the tdTomato 
fluorescent reporter, which is an indicator of Cre expression.  Green color indicates 
antibody staining for CD31, Pgp, or BCRP.  AB, arachnoid barrier.  BBB, blood-brain 
barrier.  CP, choroid plexus. 
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Figure 3-7. Continued. 
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Figure 3-8. TdTomato reporter expression in LPV-Cre/tomato mice. 
A.  Activation of the tdTomato reporter when bred with LPV-Cre mice.  B.  
Representative images of tdTomato expression of whole brain, liver, kidney, and intestine 
from age matched LPV-Cre/tomato and control (Cre negative) tomato mice (pups n = 9, 
adults n = 15).  C.  Representative images of frozen sections of LPV-Cre/tomato (n = 4) 
and control (Cre negative) tomato brain, liver, kidney, and intestine at 20X magnification.  
Dashed lines indicate the boundary of the brain ventricle that contains the CP. 
Notes:  Cell nuclei (blue) are stained with DAPI.  Red color represents the tdTomato 
fluorescent reporter, which is an indicator of Cre expression.  AB, arachnoid barrier.  
BBB, blood-brain barrier.  CP, choroid plexus. 
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Figure 3-8. Continued. 
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weak.  TdTomato expression was not visualized in any endothelial or AB cells, and did 
not differ between males and females, but mice did seem to show a correlation of 
increasing fluorescent signal with increase in age from P8 to adult (7 weeks) seen in 
Figure 3-8C. 
For further characterization, we also performed IHC with CD31, Pgp, and BCRP 
markers.  TdTomato expression did not co-localize with CD31 (no yellow/orange color) 
indicating this LPV-Cre model does not have any expression within endothelial cells.  
The staining of BCRP and tdTomato fluorescence seems to be overlapping within the CP 
epithelium (Figure 3-9A).  BCRP is expressed on the apical (CSF-facing) surface of 
mouse CP epithelial cells whereas Pgp is not expressed in mouse CP.  Expression of Pgp 
at the CP is currently a source of contention within the literature [7-10], but our results 
conclude that mice do not express Pgp at the CP.  Overall, these results suggest this LPV-
Cre model is suitable for conditionally deleting BCRP in the mouse CP, but will make no 
impact on Pgp due to lack of expression at this site.  The LPV-Cre/tomato mice also do 
not show any tdTomato expression in other organs (Figure 3-9B). 
Characterization of Pgp and BCRP Conditional Knockout Mice 
Ptgds-Cre, Cdh5-Cre, and LPV-Cre mice homozygous for the Cre transgene were 
bred with Pgp-flox and BCRP-flox mice homozygous for the floxed allele.  Offspring 
produced from these crosses were interbred to obtain mice that were confirmed to be 
homozygous for both the Cre transgene and the conditional knockout allele, which is 
determined by MLPA and PCR genotyping.  These homozygous Cre/flox mice are the 
conditional knockout (cKO) mice and were used to characterize the status of Pgp and 
BCRP proteins in the AB, BBB, and CP of the brain by using traditional colorimetric 
IHC.  Liver, kidney, and intestine tissues were also analyzed, but the wild-type control 
did not stain well and therefore makes it difficult to compare the control and cKO groups.  
The same antibody dilution and experimental conditions are not always the same for all 
tissues and each tissue may not express the same amount of Pgp or BCRP protein, so 
more optimization will be required for these tissues in order to correctly compare control 
and cKO groups. 
Analysis of immunohistochemistry from Pgp conditional knockout mice 
As discussed previously, Pgp can be found at the AB and BBB within the CNS.  
Although Pgp’s expression at the CP is controversial, our results consistently prove that 
Pgp is not located within the CP of mice.  Wild-type mouse brain stained with our Pgp 
antibody was used as a positive control, while an isotype control antibody was used for a 
negative control.  Isotype antibodies are used to control for background issues sometimes 
seen when other regions of the antibody or its epitope bind other proteins or structures 
non-specifically.  Wild-type mouse tissues showed strong Pgp expression in the brain 
specifically in the AB and BBB while the CP was negative, as expected.
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Figure 3-9. Immunohistochemistry with CD31, Pgp, and BCRP markers in 
comparison to native tdTomato expression in LPV-Cre/tomato mice. 
A.  Sequential frozen brain sections stained with CD31 (endothelial cell marker), Pgp, 
and, BXP-53 (BCRP) antibodies.  Images captured at 20X magnification.  B.  Sequential 
frozen liver, kidney, and intestine sections stained with CD31 (endothelial cell marker), 
Pgp, and, BXP-53 (BCRP) antibodies.  Images captured at 20X magnification. 
Notes:  Cell nuclei (blue) are stained with DAPI.  Red color represents the tdTomato 
fluorescent reporter, which is an indicator of Cre expression.  Green color indicates 
antibody staining for CD31, Pgp, or BCRP.  AB, arachnoid barrier.  BBB, blood-brain 
barrier.  CP, choroid plexus. 
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Figure 3-9. Continued. 
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 For the Pgp-AB KO (Ptgds-Cre x Pgp-flox) mouse, deletion of Pgp at the AB and 
possibly at the BBB was expected due to evidence from the Ptgds-Cre/tdTomato 
characterization for Cre expression.  This ablation pattern of Pgp expression in the brain 
was confirmed by IHC (Figure 3-10).  It was clear that the AB layer did not express any 
Pgp, but the BBB compartment was a little more difficult to interpret.  It seems that some 
vessels were negative for Pgp staining, while others were positive for Pgp.  
Characterization of more animals will help determine if this is a true phenotype or just a 
consequence of the genetics of one animal. 
 In the Pgp-BBB KO (Cdh5-Cre x Pgp-flox) mice, Pgp deletion was expected in 
only the endothelial cells due to strong evidence from the Cdh5-Cre/tdTomato 
characterization data previously shown above.  The AB and CP sites of the cKO brain 
looked identical to the wild-type mouse as expected; positive AB and negative CP.  The 
brain endothelial expression of Pgp in this cKO was present but fainter in comparison to 
wild-type (Figure 3-10).  This result was very surprising given the strong Cre expression 
seen in endothelial cells of the Cdh5-Cre/tomato mouse.  There is a possibility that the 
floxed allele is not being excised fully for some cells, or Cre is not being expressed in 
100% of the endothelial cells of the brain – although the Cdh5-Cre/tdTomato 
characterization data suggests Cre/tdTomato is expressed in at least the majority of 
endothelial cells of the brain. 
 The expectation for the Pgp-CP KO (LPV-Cre x Pgp-flox) mouse was that it 
would be identical to wild-type due to the lack of Pgp expression in the CP of mice.  This 
cKO resulted in a Pgp staining pattern identical to a wild-type mouse brain; positive AB 
and BBB, while CP was negative (Figure 3-10). 
Analysis of immunohistochemistry from BCRP conditional knockout mice 
 As discussed previously, BCRP can be found at the AB, BBB, and CP within the 
CNS.  BCRP is also known to be located in bile canaliculi of liver, kidney tubules, and 
the surface of intestinal epithelium.  Wild-type mouse tissues stained with BXP-53 
antibody for BCRP served as a positive control, while an isotope control antibody was 
used as a negative control.  Wild-type mouse tissues showed strong and consistent BCRP 
expression in all three CNS barrier compartments as well as liver, kidney, and intestine as 
expected. 
For the BCRP-AB KO (Ptgds-Cre x BCRP-flox) mouse, deletion of BCRP at the 
AB and possibly at the BBB was expected due to evidence from the Ptgds-Cre/tdTomato 
characterization for Cre expression.  BXP-53 staining showed no ablation of BCRP at the 
AB or BBB.  Deletion of BCRP was only seen in the CP, but as an incomplete deletion 
(Figure 3-11).  This partial ablation could be due to this mouse still having one wild-type 
(non-floxed) BCRP allele, as we have not yet reached homozygosity of the BCRP-floxed 
alleles yet in our breeding scheme.  Recalling the results for the Pgp-AB KO, the 
difference in phenotype between the Pgp-AB KO and the BCRP-AB KO is actually quite 
telling.  As reported above, the Ptgds-Cre mouse has some variation in its offspring  
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Figure 3-10. Immunohistochemistry of cKO brain tissue from Cre/Pgp-floxed 
mice. 
Brain sections from each cKO model stained with our Pgp antibody at 1:400,000 dilution.  
Wild-type tissue was from Pgp-floxed mouse (Cre negative).  The Pgp-AB KO (n = 1) is 
the result of breeding Ptgds-Cre and Pgp-floxed mice.  The Pgp-BBB KO (n = 2) is the 
result of breeding Cdh5-Cre and Pgp-floxed mice.  The Pgp-CP KO (n = 1) is the result 
of breeding LPV-Cre and Pgp-floxed mice. 
Notes:  AB, arachnoid barrier.  BBB, blood-brain barrier.  CP, choroid plexus.
 46
 47
Figure 3-11. Immunohistochemistry of cKO brain tissue from Cre/BCRP-floxed 
mice. 
Brain sections from each cKO model stained with our BXP-53 antibody for BCRP at 
1:2,000 dilution.  Wild-type tissue was from BCRP-floxed mice (Cre negative).  The 
BCRP-AB KO (n = 1) is the result of breeding Ptgds-Cre and BCRP-floxed mice.  The 
Pgp-BBB KO (n = 2) is the result of breeding Cdh5-Cre and BCRP-floxed mice.  The 
Pgp-CP KO (n = 2) is the result of breeding LPV-Cre and BCRP-floxed mice. 
Notes:  AB, arachnoid barrier.  BBB, blood-brain barrier.  CP, choroid plexus. 
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which resulted in mice not being genetically identical even though all mice stem from the 
same transgenic founder.  This may be why we are seeing the deletion of transporters in 
different compartments between the Pgp and BCRP cKOs generated using the Ptgds-Cre 
model.  BCRP expression in liver, kidney, and intestine from this cKO was identical to 
wild-type indicating no peripheral deletion of BCRP outside of the brain. 
 BCRP deletion was expected to be in the endothelial cells of BCRP-BBB KO 
(Cdh5-Cre x BCRP-flox) mice, due to strong evidence from the Cdh5-Cre/tdTomato 
characterization data previously shown above.  This cKO showed positive BCRP staining 
in the AB and CP, which is identical to wild-type, and partial deletion of BCRP in the 
brain endothelial cells (Figure 3-11).  This deletion within the endothelial cells is 
different from the Pgp-BBB KO in that some vessels are completely negative (indicating 
full deletion) and other vessels were identical to wild-type stained vessels.  There seemed 
to be no correlation to vessel size or location.  This result again was very surprising given 
the strong Cre expression seen in endothelial cells of the Cdh5-Cre/tdTomato mouse.  
There is a possibility that the floxed allele is not being excised fully in some cells or Cre 
is not being expressed in all of the endothelial cells of the brain.  BCRP expression in 
liver, kidney, and intestine from this cKO was identical to wild-type indicating no 
deletion of BCRP outside of the brain. 
 In the BCRP-CP KO (LPV-Cre x BCRP-flox) mice, BCRP deletion was expected 
in only the CP, while the AB and BBB should look identical to wild-type.  However, IHC 
staining with BXP-53 antibody for BCRP showed no CP ablation, resulting in all 
compartments staining identical to wild-type mouse brain (Figure 3-11).  It is possible 
that the viral control region is not driving enough Cre for exon 2 of BCRP to be excised.  
No differences were discovered between the CP KO transporter models since the BCRP-
CP KO is the only CP KO model for mice (due to the lack of Pgp expression in the CP).  
BCRP expression in liver, kidney, and intestine from this cKO was identical to wild-type 
mice indicating no peripheral deletion of BCRP outside of the brain. 
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CHAPTER 4.   CONCLUSION 
Ptgds-Cre as a Model of Arachnoid Barrier Deletion of Pgp and BCRP 
Although Ptgds-Cre mice have shown to be capable of deleting ABC transporters 
from select brain compartments, results have been inconsistent and varied between 
animals.  The expectation of Ptgds localization in the brain from literature supports 
targeting the AB and CP.  Originally this model was meant for AB specific deletion of 
ABC transporters but upon learning of Ptgds localization in the CP, it could serve as an 
ideal BCSFB model.  We have shown deletion of Pgp in the AB and partial deletion of 
BCRP in the CP (recall this model only had one BCRP-floxed allele), but this has raised 
the question of why do we not see the same pattern of ablation when using the same Cre 
line. The genotyping was confirmed several times to ensure homozygosity of Cre and the 
transporter floxed allele.  Currently, these cKO mice, homozygous for Cre and floxed 
alleles, are being maintained for continued study.  Multiple rounds of breeding could 
possibly clear up this variation seen with initial animals, possibly due to an unpure 
genetic background of the F1 generation of cKOs.  This model can be used for pilot drug 
studies looking at pharmacokinetics of specific Pgp and BCRP substrates and their 
disposition in the brain. 
Cdh5-Cre as a Model of Endothelial Cell Deletion of Pgp and BCRP 
 The Cdh5-Cre model had the most convincing evidence for Cre localization by 
the tdTomato reporter, where it is clear that Cre is localized to endothelial cells only.  
Cre/tdTomato expression was consistent and strong without variation between animals.  
To our surprise the cKO animals did not recapitulate the tdTomato phenotype in targeting 
the endothelial cells.  BCRP was lost in only some of the brain endothelial cells while 
deletion of Pgp was weak in the BBB cKOs.  The promoter seems robust and specific 
enough to drive Cre expression in endothelial cells.  The only inadequacy could be that 
the promoter is not targeting all endothelial cells, but upon evaluating the tdTomato 
characterization it seems all or at least a great majority of the endothelial cells are 
expressing the Cre enzyme. It is unclear why loss of Pgp and BCRP in the endothelial 
cells is not occurring.  Characterizing additional animals will aide in confirming the cKO 
phenotype for these mice. 
LPV-Cre as a Model of Choroid Plexus Deletion of Pgp and BCRP 
 The LPV-Cre model had the weakest expression of tdTomato (Cre expression). 
This raised the question of whether this weak expression would result in enough Cre to 
excise the ABC transporter floxed alleles.  After staining the cKO tissues for BCRP it 
became clear that there is not enough Cre for excision.  While the Pgp-CP KO does not 
seem useful since mice do not express Pgp in the CP, we initially thought that mice 
would express Pgp since other mammals do (i.e. humans).  In light of the incapability of 
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LPV-Cre to knockout proteins in the CP, the Ptgds-Cre model may serve for this 
compartment.  We could then simply compare a BBB KO to an AB/CP KO where they 
would represent the comparison between the BBB versus the BCSFB, respectively. 
Significance of Using Conditional Knockouts of Pgp and BCRP in the Brain 
 Global Pgp and BCRP knockout mice have shown the importance of these drug 
transporters to drug movement, specifically at the BBB.  However, due to the unique 
localization and expression level of Pgp and BCRP between the AB, BBB, and CP, 
global deletion of transporters cannot tease apart each barriers influence on drug 
movement.  Since many therapeutic agents are or could be substrates from Pgp and 
BCRP, it is crucial for the development of novel drugs to estimate the role of each 
transporter within each barrier (AB, BBB, and CP).  These cKO models have the 
potential to answer these questions.  As a growing number of drugs are given IT, an 
understanding of how drug transporters at the AB and CP modulate or prevent drugs from 
blood to CSF will open the door to new strategies to improve drug delivery to the CSF.  
IT delivery of drugs is common to patients that experience metastasis of cancer cells to 
the CSF.  The CSF harbors and protects these cells from chemotherapeutics given IV 
with help from drugs transporters at the BBB.  With the aide of cKO models, drug 
penetration at the BBB versus the BCSFB can be studied as well as the comparison of the 
contribution of Pgp and BCRP at each barrier.  Blood to CSF drug penetration is no 
longer only determined by the BBB and CP, but also influenced by the AB.  Adding this 
level of complexity also supports the use of cKOs to determine the regional influence of 
drug transporters at the three barrier sites. 
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